Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33705
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOpat, Stephen S-
dc.contributor.authorTedeschi, Alessandra-
dc.contributor.authorHu, Bei-
dc.contributor.authorLinton, Kim M-
dc.contributor.authorMcKay, Pamela-
dc.contributor.authorLeitch, Sophie-
dc.contributor.authorColeman, Morton-
dc.contributor.authorZinzani, Pier Luigi-
dc.contributor.authorJin, Jie-
dc.contributor.authorSun, Mingyuan-
dc.contributor.authorSobieraj-Teague, Magdalena-
dc.contributor.authorBrowett, Peter J-
dc.contributor.authorKe, Xiaoyan-
dc.contributor.authorThieblemont, Catherine-
dc.contributor.authorArdeshna, Kirit M-
dc.contributor.authorBijou, Fontanet-
dc.contributor.authorWalker, Patricia A-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorHo, Shir-Jing-
dc.contributor.authorZhou, Keshu-
dc.contributor.authorLiang, Zhiyu-
dc.contributor.authorXu, Jianfeng-
dc.contributor.authorTankersley, Chris-
dc.contributor.authorDelarue, Richard-
dc.contributor.authorCo, Melannie-
dc.contributor.authorTrotman, Judith-
dc.date2023-
dc.date.accessioned2023-09-13T04:43:29Z-
dc.date.available2023-09-13T04:43:29Z-
dc.date.issued2023-11-28-
dc.identifier.citationBlood Advances 2023-11-28; 7(22)en_US
dc.identifier.issn2473-9537-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33705-
dc.description.abstractThe primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), with a favorable safety/tolerability profile. Presented here is the final analysis of MAGNOLIA, performed to characterize the durability of response and longer-term safety and tolerability. Zanubrutinib (160 mg twice daily) was evaluated in 68 patients with R/R MZL who had received at least 1 anti-CD20-directed regimen. The primary endpoint was independent review committee (IRC)-assessed ORR. Secondary endpoints included investigator-assessed ORR, duration of response (DOR), progression-free survival (PFS), overall survival (OS), health-related quality of life, safety, and tolerability. With a median follow-up of 27.4 months, the IRC-assessed ORR was 68.2% (95% confidence interval [CI], 55.6%-79.1%), with a 24-month DOR event-free rate of 72.9% (95% CI, 54.4%-84.9%). PFS and OS at 24 months were 70.9% (95% CI, 57.2%-81.0%) and 85.9% (95% CI, 74.7%-92.4%), respectively. The zanubrutinib safety profile was consistent with the primary analysis, with no new safety signals observed. Atrial fibrillation/flutter (n = 2 [2.9%]) and hypertension (n = 3 [4.4%]) were uncommon. Neutropenia (n = 8 [11.8%]) was the most common grade ≥3 adverse event. In this final analysis of MAGNOLIA, zanubrutinib demonstrated sustained clinical responses beyond 2 years, with 73% of responders alive and progression-free. Zanubrutinib continued to demonstrate a favorable safety/tolerability profile with the additional time on treatment. This trial was registered at www.clinicaltrials.gov as #NCT03846427.en_US
dc.language.isoeng-
dc.titleSafety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBlood Advancesen_US
dc.identifier.affiliationMonash Health, Clayton, Australia.en_US
dc.identifier.affiliationASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milano, Italy.en_US
dc.identifier.affiliationAtrium Health Levine Cancer Institute, Charlotte, North Carolina, United States.en_US
dc.identifier.affiliationThe Manchester Cancer Research Centre, Manchester, United Kingdom.en_US
dc.identifier.affiliationBeatson West of Scotland Cancer Centre, Glasgow, United Kingdom.en_US
dc.identifier.affiliationNorth Shore Hospital, Auckland, New Zealand.en_US
dc.identifier.affiliationClinical Reliance Alliance, Lake Success, New York, United States.en_US
dc.identifier.affiliationUniversity of Bologna, Bologna, Italy.en_US
dc.identifier.affiliationFirst Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China.en_US
dc.identifier.affiliationnstitute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.en_US
dc.identifier.affiliationFlinders Medical Centre, Bedford Park, Australia.en_US
dc.identifier.affiliationThe University of Auckland, Auckland, New Zealand.en_US
dc.identifier.affiliationPeking University Third Hospital.en_US
dc.identifier.affiliationAP-HP, Hôpital Saint-Louis, Hemato-oncologie, DMU DHI,F-75010 Paris, France, Paris, France.en_US
dc.identifier.affiliationUCLH, London, United Kingdom.en_US
dc.identifier.affiliationInstitut Bergonie, Bordeaux, France.en_US
dc.identifier.affiliationPeninsula Health, PARKDALE, VI, Australia.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.affiliationSt George Hospital, Kogarah, Australia.en_US
dc.identifier.affiliationHenan Cancer Hospital, Zhengzhou, China, Zhengzhou, China.en_US
dc.identifier.affiliationBeiGene, Shanghai, China.en_US
dc.identifier.affiliationBeiGene, Ridgefield Park, New Jersey, United States.en_US
dc.identifier.affiliationBeigene, San Mateo, California, United States.en_US
dc.identifier.affiliationBeiGene Switzerland GmbH, Basel, Switzerland.en_US
dc.identifier.affiliationBeigene, San Mateo, California, United States.en_US
dc.identifier.affiliationConcord Repatriation General Hospital and University of Sydney, Concord, United Kingdom.en_US
dc.identifier.doi10.1182/bloodadvances.2023010668en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-0308-6458en_US
dc.identifier.orcid0000-0002-4325-0929en_US
dc.identifier.orcid0000-0002-3294-1548en_US
dc.identifier.orcid0000-0002-3959-9730en_US
dc.identifier.orcid0000-0002-2112-2651en_US
dc.identifier.orcid0000-0001-6768-7175en_US
dc.identifier.orcid0000-0002-0376-2559en_US
dc.identifier.orcid0000-0002-5368-8975en_US
dc.identifier.orcid0000-0001-5467-1377en_US
dc.identifier.orcid0000-0001-8009-4593en_US
dc.identifier.pubmedid37682792-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Jul 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.